Aerie Pharmaceuticals Inc.

7.83-0.2900-3.57%Vol 489.47K1Y Perf -53.86%
Jun 28th, 2022 16:00 DELAYED
BID7.28 ASK8.50
Open8.08 Previous Close8.12
Pre-Market- After-Market7.44
 - -  -0.39 -4.98%
Target Price
20.63 
Analyst Rating
Moderate Buy 1.67
Potential %
163.47 
Finscreener Ranking
★★★+     52.37
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.86
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     53.40
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
21.53 
Earnings Rating
Strong Buy
Market Cap380.71M 
Earnings Date
3rd Aug 2022
Alpha-0.04 Standard Deviation0.15
Beta0.76 

Today's Price Range

7.758.14

52W Range

4.8118.84

5 Year PE Ratio Range

-11.10-5.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
18.71%
1 Month
49.82%
3 Months
-13.62%
6 Months
11.54%
1 Year
-53.86%
3 Years
-72.52%
5 Years
-85.00%
10 Years
-

TickerPriceChg.Chg.%
AERI7.83-0.2900-3.57
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.70
0.90
9.41
-1.90
Leverage Ratio -6.00
ProfitabilityValueIndustryS&P 500US Markets
86.60
-21.80
-5.80
-
-34.50
RevenueValueIndustryS&P 500US Markets
201.00M
4.13
63.33
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.65-0.66-1.54
Q04 2021-0.681.09260.29
Q03 2021-0.62-0.72-16.13
Q02 2021-0.65-0.67-3.08
Q01 2021-0.69-0.72-4.35
Q04 2020-0.75-0.79-5.33
Q03 2020-0.81-0.6519.75
Q02 2020-0.79-0.83-5.06
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.5411.48Positive
9/2022 QR-0.5015.25Positive
12/2022 FY-2.212.64Positive
12/2023 FY-1.226.87Positive
Next Report Date3rd Aug 2022
Estimated EPS Next Report-0.54
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume489.47K
Shares Outstanding48.62K
Shares Float47.58M
Trades Count7.22K
Dollar Volume3.85M
Avg. Volume672.89K
Avg. Weekly Volume726.59K
Avg. Monthly Volume679.16K
Avg. Quarterly Volume612.91K

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) stock closed at 8.12 per share at the end of the most recent trading day (a 7.41% change compared to the prior day closing price) with a volume of 623.73K shares and market capitalization of 380.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 365 people. Aerie Pharmaceuticals Inc. CEO is Vicente Anido.

The one-year performance of Aerie Pharmaceuticals Inc. stock is -53.86%, while year-to-date (YTD) performance is 15.67%. AERI stock has a five-year performance of -85%. Its 52-week range is between 4.81 and 18.84, which gives AERI stock a 52-week price range ratio of 21.53%

Aerie Pharmaceuticals Inc. currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 34.26, a price-to-sale (PS) ratio of 1.96, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -18.63%, a ROC of -21.84% and a ROE of 101.46%. The company’s profit margin is -34.50%, its EBITDA margin is -5.80%, and its revenue ttm is $201.00 Million , which makes it $4.13 revenue per share.

Of the last four earnings reports from Aerie Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. Aerie Pharmaceuticals Inc.’s next earnings report date is 03rd Aug 2022.

The consensus rating of Wall Street analysts for Aerie Pharmaceuticals Inc. is Moderate Buy (1.67), with a target price of $20.63, which is +163.47% compared to the current price. The earnings rating for Aerie Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aerie Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aerie Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.37, ATR14 : 0.55, CCI20 : 211.42, Chaikin Money Flow : 0.24, MACD : 0.24, Money Flow Index : 79.15, ROC : 33.77, RSI : 67.70, STOCH (14,3) : 94.40, STOCH RSI : 1.00, UO : 62.46, Williams %R : -5.60), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aerie Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
6 (66.67 %)
6 (66.67 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Hold
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Moderate Buy
1.67

Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.

CEO: Vicente Anido

Telephone: +1 919 237-5300

Address: 4301 Emperor Boulevard, Durham 27703, NC, US

Number of employees: 365

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

77%23%

Bearish Bullish

77%23%

Bearish Bullish

68%32%

TipRanks News for AERI

Mon, 09 May 2022 10:29 GMT Aerie Pharma (AERI) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Fri, 28 Jan 2022 14:15 GMT Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and Insulet (PODD)

- TipRanks. All rights reserved.

News

Stocktwits